Renuka Rajagopal, MD
Critical Care Medicine · Sumter, SCNPI 1912326471
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,576 of the $3,575 with a category attached, or 72.0%. 19 manufacturers reported payments, led by Noah Medical Corporation at 24.5% of the total. 2025 is the largest year on record at $2,060, more than ten times the $30 reported in 2019.
Across 103 payments — averaging $34.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Noah Medical Corporation$875
- Regeneron Healthcare Solutions, Inc.$569
- AstraZeneca$506
- Sanofi$381
- GSK$296
- Insmed, Inc.$199
- plus $749 from 13 others
What the payments were for
- Travel & lodging$89125%
- Food & beverage$2,57672%
- Education$1093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Noah Medical Corporation | 7 | $875 |
| Regeneron Healthcare Solutions, Inc. | 16 | $569 |
| AstraZeneca | 19 | $506 |
| Sanofi | 12 | $381 |
| GSK | 16 | $296 |
| Insmed, Inc. | 9 | $199 |
| Medical Device Business Services, Inc. | 1 | $161 |
| Amgen | 6 | $157 |
| Boehringer Ingelheim | 3 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Philips North America LLC | 3 | $50 |
| AbbVie | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| United Therapeutics Corporation | 1 | $30 |
| Boston Scientific | 1 | $29 |
| Viatris Specialty LLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,575 in reported general payments places this provider in the 75th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 21 | $264,726 |
| Dupixent PenDupilumab | 59 | $237,498 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 298 | $203,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 172 | $118,583 |
| Fasenra PenBenralizumab | 14 | $69,354 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 110 | $65,785 |
| Spiriva RespimatTiotropium Bromide | 82 | $50,287 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $16,935 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 92 | $16,244 |
| XolairOmalizumab | 11 | $15,013 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $14,766 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $12,758 |
| DuleraMometasone/Formoterol | 35 | $12,229 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 303 | $10,342 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $69 | $380,798213 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $506 | $216,257340 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $296 | $144,573234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Sumter
- Charlton StrangeCharleston$205K
- William AlleyneRock Hill$199K
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Daniel HerrHilton Head Island$151K
- Hafez HayekConway$138K
- Nicholas FoxCharleston$88K
- Nasir AwanGreenville$54K
- Christopher GilbertCharleston$44K
- Ikenna OnyebuekeSpartanburg$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.